Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

B 1451

Drug Profile

B 1451

Alternative Names: B-1451; Fc-HM-3; HM-3-Fc

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tasly Biopharmaceuticals
  • Class Antirheumatics; Eye disorder therapies; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
  • Mechanism of Action Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration
  • No development reported Rheumatoid arthritis

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in China (SC, Injection)
  • 20 Jul 2022 Preclinical trials in Age-related macular degeneration in China (Parenteral), before July 2022
  • 19 Jul 2022 Tasly Biopharmaceuticals has patents pending for HM-3 fusion protein in China, Japan, Canada, European Union, Taiwan, South Korea and USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top